Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin

seekingalpha11-27

Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials.SAVA stock ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486857065?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2021145941/image_2021145941.jpg","is_english":true,"pubTime":"2024-11-27 04:30","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2486857065","market":"fut","top_or_hot":-1,"title":"Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin","media":"seekingalpha","content":"<div>\n<p>Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials.SAVA stock ...</p>\n\n<a href=\"https://seekingalpha.com/article/4740470-cassava-sciences-phase-3-alzheimers-drug-fail-final-nail-in-coffin\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 04:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4740470-cassava-sciences-phase-3-alzheimers-drug-fail-final-nail-in-coffin><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials.SAVA stock ...</p>\n\n<a href=\"https://seekingalpha.com/article/4740470-cassava-sciences-phase-3-alzheimers-drug-fail-final-nail-in-coffin\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://seekingalpha.com/article/4740470-cassava-sciences-phase-3-alzheimers-drug-fail-final-nail-in-coffin","article_id":"2486857065","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2021145941/image_2021145941.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486857065","pubTimestamp":1732653034,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials.SAVA stock ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4007":"制药","SAVA":"Cassava Sciences Inc"},"translate_title":"Cassava Sciences：三期阿尔茨海默氏症药物失败是棺材上的最后一颗钉子","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9},"content_text":"Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials.SAVA stock plummeted from $26.5 to $4 per share following the negative study results, casting doubt on the company's future prospects.Cassava's remaining $149m cash and lack of ongoing R&D expenses may lead to delisting or a reverse merger with another biotech firm.The failure of simufilam underscores the challenges in developing effective Alzheimer's treatments, with Cassava likely exiting the AD drug development space.   J Studios/DigitalVision via Getty Images Cassava Sciences Investment Overview I covered Cassava Sciences' (NASDAQ:SAVA) Q3 earnings earlier this month - a low-key affair from which most of the key figures behind the company's extraordinary rise, fall, rise, and fall again story were absent, including even the current Chief Medical","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"analysis","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486857065"}